• T W Kassem, O Abdelaziz, and S Emad-Eldin.
• Diagnostic and Intervention Radiology Department, Cairo University Hospitals, El-Manial Street, 11956 Cairo, Egypt. Electronic address: tamerwahid@hotmail.com.
• Diagn Interv Imaging. 2017 Oct 1; 98 (10): 693-698.

PurposeThe purpose of this study was to evaluate the clinical utility of 2-[18F] fluoro-2-deoxy-D-glucose (18FDG) positron emission tomography (PET)/computed tomography (CT) (18F-FDG-PET/CT) in the follow-up of adult patients with soft tissue sarcomas.Materials And MethodsWe prospectively evaluated 37 consecutive patients with known soft tissue sarcoma with 18F-FDG-PET/CT examination for suspected recurrence of disease. They were 21 men and 16 women with a mean age of 49.6±10.6 (SD) years (range, 34-75years). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG-PET/CT examination were calculated on a per patient basis.Results18F-FDG-PET/CT showed an overall diagnostic accuracy of 91.8%, sensitivity of 90% and a specificity of 100%. The positive predictive value and negative predictive value were 100 and 70%, respectively. The 18F-FDG-PET/CT interpretations were correct in 34/37 patients (91.8%). Incorrect interpretations occurred in three patients (8.1%). Reasons for false negative findings were low 18F-FDG uptake of local recurrence in one patient and low 18F-FDG uptake of subcentimetric inguinal lymph node metastases.Conclusion18F-FDG-PET/CT has a high diagnostic value in the follow-up of patients with soft tissue sarcoma.Copyright © 2017 Editions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

26 keywords...

hide…